Merrell Dow's eflornithine
Firm announced that 49 of 66 patients with pneumocystis carinii completing a 14 day treatment cycle with the drug were cured of the pneumonia. Merrell Dow said it received a total of 150 case reports of patients who received the drug under compassionate use, however, 84 patients did not complete the full cycle treatment. FDA recently granted the investigational compound orphan drug status for use in pneumocystis carinii and African sleeping sickness. The drug is currently in Phase III clinicals for pneumonia.
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.